AN2 Therapeutics, Inc. (ANTX) income statement
ANTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 8/30
$4.95+0.72 (+17.02%)
Close on Nov 18, 2026Market cap $186.79MP/E –Yield –
AN2 Therapeutics, Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, FY
- Gross margin
- –
- Operating margin
- –
- Net margin
- –
- Return on equity, FY2025
- -52.1%
Financial strength
- Current ratio
- 14.32
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 793.5%
Valuation
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 2.46
- Dividend yield
- –
See a number that looks wrong?